NLS Biotech News

ResoTher Pharma has reported promising Phase 2a results for its cardioprotective drug candidate RTP-026, moving the company a step closer to a key efficacy trial and a potential pharma partnership or sale.

In the phase 3 STEP Young trial, 40.4% of children aged 6 to under 12 treated with once-weekly semaglutide were no longer classified as having obesity after 68 weeks, compared with none of those on placebo.

A post-hoc analysis of SynAct Pharma’s Phase 2b ADVANCE study confirms earlier positive results for resomelagon in rheumatoid arthritis (RA), and the company now plans to discuss Phase 3 trial design with the FDA in Q4 2026.

The company has completed the eight-week treatment period for all patients in its pivotal Phase III HEEALING1 study of linaprazan glurate in erosive gastroesophageal reflux disease (GERD), with topline results now expected in the fourth quarter of 2026.

AstraZeneca and partner Amgen have reported that Tezspire (tezepelumab) met both co-primary and all key secondary endpoints in the Phase III CROSSING trial in eosinophilic esophagitis (EoE), positioning the anti-TSLP antibody for a potential new indication beyond its existing approvals in severe asthma and chronic rhinosinusitis with nasal polyps.

Faron Pharmaceuticals has announced that the first patient has been enrolled in the BEXAR trial, testing its lead candidate bexmarilimab in combination with chemotherapy as a first-line treatment for metastatic soft-tissue sarcoma.

Lytix Biopharma is joining a new investigator-initiated Phase II study, ALETTA, that will test its lead candidate ruxotemitide in combination with ipilimumab and nivolumab in patients with early-stage, resectable melanoma – a second major checkpoint-inhibitor combination alongside the company’s existing pembrolizumab work.

Swedish biotech BioInvent has published preclinical data on its two anti-TNFR2 antibodies, BI-1808 and BI-1910, in the journal Cancer Research, showing the two candidates drive anti-tumour immunity through distinct mechanisms – including in tumour types that typically resist checkpoint inhibitor therapy.

Merck and Moderna have reported positive topline results from the Phase 3 INTerpath-001 trial of intismeran autogene in combination with Keytruda in patients with completely resected, high-risk melanoma.

The company has received regulatory approval from the European Medicines Agency, to conduct PP-CT04, a two-part, randomized, double-blind, placebo-controlled, parallel-group, 12‑week trial investigating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in obese participants.